

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(2) Items and Amounts of Extraordinary Profits and Losses

— Profit Loss

Currency: RMB Unit: Yuan

Items	Amounts from the third quarter of 2022	Amounts from the beginning of the year to the end of the Reporting Period	Description
1. 非经常性损益项目 (非流动资产处置损益、计入当期损益的政府补助、除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、交易性金融负债产生的公允价值变动损益，以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益)	720,70.62	65,736.5	
2. 非经常性损益项目 (非流动资产处置损益、计入当期损益的政府补助、除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、交易性金融负债产生的公允价值变动损益，以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益)	1,326,556.5	32,71,75.34	
3. 非经常性损益项目 (非流动资产处置损益、计入当期损益的政府补助、除同公司正常经营业务相关的有效套期保值业务外，持有交易性金融资产、交易性金融负债产生的公允价值变动损益，以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益)	172.00	-0.025	,736.5

Sei V un K -spazio vettoriale, φ un K -endomorfismo di V . Si ha $\varphi^2 = \varphi$ se e solo se φ è un K -proiettore.

$$\square \quad \varphi^2 = \varphi \iff \varphi \circ \varphi = \varphi$$

Se φ è un K -proiettore, si ha $\varphi^2 = \varphi$. Viceversa, se $\varphi^2 = \varphi$, si ha $\varphi \circ \varphi = \varphi$.

1. Balance sheet items

Items	As at the end of the Reporting Period	As at the end of last year	Year-on-year increase/decrease	Reasons for changes
Assets	6,070,007.3	10,00,75 . 6	. 3 .36%	
Liabilities	6,503,40 , .32	4,707,54 ,5 2.43	3 .15%	
Equity	20,557,35 .51	14, , 2, 21.5	37.11%	
Current assets	301,261,305.2	204,063, 3 .27	47.63%	
Non-current assets	3,046, 2 , 03.75	1, 6,2 4,700.56	61.53%	
Current liabilities	4 6,111, 43.1			
Non-current liabilities				
Equity				

Items	As at the end of the Reporting Period	As at the end of last year	Year-on-year increase/decrease	Reasons for changes
Revenue	3,341,000.37	275,353,306.24	3.27%	Revenue increased by 3.27% compared to the same period last year, primarily due to an increase in sales volume and price realization.
Operating Expenses	1,246,150.00	1,356,155.51	204.7%	Operating expenses decreased by 204.7% compared to the same period last year, primarily due to a significant reduction in depreciation and amortization expenses.

2. Income statement items

Items	The Reporting Period	Same period of last year	Year-on-year increase/decrease	Reasons for changes
Operating Profit	166,535,200.66	10,373,700.73	52.2%	Operating profit increased by 52.2% compared to the same period last year, primarily due to an increase in operating income and a decrease in operating expenses.
Operating Loss	53,515,004.12	230,144,413.70	123.17%	Operating loss decreased by 123.17% compared to the same period last year, primarily due to a significant reduction in depreciation and amortization expenses.
Profit Before Tax	32,710,753.34	22,166,104.73	47.61%	Profit before tax increased by 47.61% compared to the same period last year, primarily due to an increase in operating profit and a decrease in operating loss.

q7t-s	The Reporting Period	Same period of last year	Year-on-year increase/decrease	Reasons for changes
	1, 21,2 2.6	26,7 5, 4.6	405. 4%	
	14,746,57 .3	6, 4,547.46	114.20%	
	17,111, 17.61	11,7 5,24 . 0	45.07%	
	4,475,25 .23	2, 23,54 .16	53.0 %	
	777,1 4.3	1, 2 ,3 . 5	5 .70%	
	411 14,322.53	565,025,657.56	7 430%23	14.1 0, 335.6246 (5 .70%) 52 .

Items	The Reporting Period	Same period of last year	Year-on-year increase/decrease	Reasons for changes
Revenue	1,053,241.5	6,437,623.23	↓ 3.64%	Revenue decreased by 3.64% compared to the same period of last year, primarily due to a decrease in sales volume and a decline in average selling prices.
Cost of sales	41,053,361.37	553,666,240.2	↓ 51.1%	Cost of sales decreased by 51.1% compared to the same period of last year, mainly due to a significant reduction in the cost of raw materials and lower production costs.
Operating expenses	↓ 1,031,762.00	↓ 6,603,633.55	↓ 7.75%	Operating expenses decreased by 7.75% compared to the same period of last year, due to cost-cutting measures and a reduction in administrative and sales expenses.
Profit before tax	650,063,513.7	457,062,547.37	42.23%	Profit before tax increased by 42.23% compared to the same period of last year, driven by the significant decrease in cost of sales and operating expenses.

3. Cash flow items

Items	The Reporting Period	Same period of last year	Year-on-year increase/decrease	Reasons for changes
Cash generated from operations	71,210,114	122,722,540	↓ 6.10%	Cash generated from operations decreased by 6.10% compared to the same period of last year, primarily due to a decrease in operating profit and a reduction in non-cash adjustments.

Items	The Reporting Period	Same period of last year	Year-on-year increase/decrease	Reasons for changes
Interest income	2,353,702.24	1,037,327.22	127.77%	Interest income increased due to the increase in the average balance of interest-bearing assets.
Interest expense	70,216,607.77	467,723.55	307.43%	Interest expense increased due to the increase in the average balance of interest-bearing liabilities.
Net interest income	10,550,037.54	27,354,460.60	13.64%	Net interest income decreased due to the increase in interest expense.
Net interest margin	263,74,375.54	664,31,021.34	60.32%	Net interest margin decreased due to the increase in interest expense.

BUSINESS REVIEW

The Company's primary business is the development, production, and sale of pharmaceutical products. The Company's products are primarily used in the treatment of various chronic diseases, including cardiovascular disease, diabetes, and obesity. The Company's products are sold in the United States and other countries. The Company's primary market is the United States, where it has a significant market share. The Company's products are sold through a network of distributors and retailers. The Company's primary source of revenue is the sale of its pharmaceutical products. The Company's primary expenses are the cost of research and development, manufacturing, and marketing. The Company's primary risk is the loss of its market share to competitors. The Company's primary goal is to increase its market share and revenue.

The Company's primary business is the development, production, and sale of pharmaceutical products. The Company's products are primarily used in the treatment of various chronic diseases, including cardiovascular disease, diabetes, and obesity. The Company's products are sold in the United States and other countries. The Company's primary market is the United States, where it has a significant market share. The Company's products are sold through a network of distributors and retailers. The Company's primary source of revenue is the sale of its pharmaceutical products. The Company's primary expenses are the cost of research and development, manufacturing, and marketing. The Company's primary risk is the loss of its market share to competitors. The Company's primary goal is to increase its market share and revenue. (API-)

The Company's primary business is the development, production, and sale of pharmaceutical products. The Company's products are primarily used in the treatment of various chronic diseases, including cardiovascular disease, diabetes, and obesity. The Company's products are sold in the United States and other countries. The Company's primary market is the United States, where it has a significant market share. The Company's products are sold through a network of distributors and retailers. The Company's primary source of revenue is the sale of its pharmaceutical products. The Company's primary expenses are the cost of research and development, manufacturing, and marketing. The Company's primary risk is the loss of its market share to competitors. The Company's primary goal is to increase its market share and revenue. (CDMO-)

Heparin Industrial Chain Business

4,611.3 million yuan (down 4.0% from 4,824.5 million yuan in 2021), an increase of 43.5% (vs. 43.5% in 2021) and 56.5% (vs. 56.5% in 2021).

2,315.2 million yuan (down 31.1% from 3,368.6 million yuan in 2021), an increase of 32.7% (vs. 32.7% in 2021).

26.2% (vs. 26.2% in 2021), an increase of 144.6% (vs. 144.6% in 2021) and 77.5% (vs. 77.5% in 2021).

2,201.6 million yuan (down 1.5% from 2,236.0 million yuan in 2021), an increase of 1.5% (vs. 1.5% in 2021).

The following text is a dense block of illegible characters, possibly representing a corrupted document or a heavily stylized font. The characters are small, black, and arranged in a grid-like pattern across the page. The text is completely unreadable due to the lack of recognizable words or symbols.

The following text is another dense block of illegible characters, similar to the first block. It consists of a series of small, black, and unrecognizable symbols that do not form any legible text. The layout is consistent with the first block, appearing as a solid field of noise.

II. INFORMATION OF THE SHAREHOLDERS

(1) Table of total number of ordinary shareholders, the number of preferred shareholders whose voting rights have been restored and shareholdings of the top 10 shareholders

Unit: Share(s)

Total number of ordinary shareholders as at the end of the Reporting Period		26,203		Total number of preferred shareholders (if any) whose voting rights have been restored as at the end of the Reporting Period		0	
Shareholding of the top 10 shareholders							
Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Status of shares pledged, marked or frozen		
					Status of shares	Number	
#1 中國建設銀行股份有限公司	國家股	32.31%	474,021,000	0			
中國建設銀行股份有限公司	國家股	27.1%	401,041,200	0			
中國建設銀行股份有限公司	國家股	14.6%	214,440,000	0			
中國建設銀行股份有限公司	國家股	3.16%	46,425,600	0			
中國建設銀行股份有限公司	國家股	2.75%	40,320,000	0			
中國建設銀行股份有限公司	國家股	1.64%	24,130,651	0			
中國建設銀行股份有限公司	國家股	1.03%	15,111,035	0			
中國建設銀行股份有限公司	國家股	0.71%	10,467,720	0			
中國建設銀行股份有限公司	國家股	0.27%	3,972,265	0			
中國建設銀行股份有限公司	國家股	0.26%	3,626,264	0			

III. OTHER IMPORTANT EVENTS

□ 2022年9月30日 人民币

IV. QUARTERLY FINANCIAL STATEMENTS

(1) Financial Statements

1. Consolidated Balance Sheet

人民币

Currency: RMB Unit: Yuan

Items	September 30, 2022	2022年9月30日
Current assets:		
货币资金	2,947,231,848.07	2,442,570,612.12
应收账款		
预付款项		
其他应收款	1,250,782,145.17	1,157,143.06
存货		
其他流动资产	6,070,007.38	10,007,751.6
流动资产合计	1,586,989,756.41	1,514,444,200
非流动资产:		
长期股权投资		
固定资产	201,578,118.74	1,230,613.3
无形资产		
开发支出		
其他非流动资产		
非流动资产合计	173,625,047.99	243,114,425.25
资产总计		
流动资产	6,503,409,988.32	4,707,541,243.43
非流动资产	20,557,358.51	14,121,521.5
资产总计		
流动资产	193,439,468.14	151,201,475.27
非流动资产	12,883,683,738.73	10,761,653,462.6

Items	September 30, 2022	July 31, 2022
Non-current assets:		
Land		
Buildings		
Equipment		
Investment properties	1,457,874.01	1,520,200.00
Investment properties under development	1,062,848,714.35	1,146,464,300.04
Intangible assets	515,178,450.76	474,471,200.00
Other non-current assets	929,164,971.71	929,164,971.12
Prepaid expenses		
Receivables	1,951,655,326.78	1,951,655,326.78
Other receivables	462,164,179.21	425,347,310.01
Other receivables		
Other receivables		
Other receivables	125,780,302.18	126,152,050.00
Other receivables	540,237,271.36	546,67,744.36
Other receivables	48,560,405.23	48,560,405.23
Other receivables	2,396,630,597.70	2,152,201,146.76
Other receivables	115,225,316.41	116,10,345.50
Other receivables	135,250,767.58	121,717,732.33
Other receivables	301,261,305.28	204,063,300.00
Other receivables	8,585,415,482.56	8,585,415,482.56
Other receivables	21,469,099,221.29	21,469,099,221.29
Current liabilities:		
Accounts payable	3,046,828,803.75	3,046,828,803.75
Accounts payable		
Accounts payable		
Accounts payable		
Accounts payable		
Accounts payable		

Items	September 30, 2022	July 31, 2022
Accounts payable	433,516,795.52	357,664,507.07
Accounts receivable		
Prepaid expenses	461,708,853.20	337,215.25
Income tax receivable		
Other receivables		
Due from related parties		
Due to related parties		
Due to subsidiaries		
Due to joint ventures		
Due to associates	150,212,971.31	156,261,106.6
Due to other parties	119,633,284.22	15,716,606.60
Other receivables	357,096,121.20	403,221,557.47
Prepaid expenses		
Other receivables	31,808,587.27	
Income tax receivable		
Other receivables		
Due from related parties		
Due to related parties		
Due to subsidiaries		
Due to joint ventures		
Due to associates	1,669,376,634.61	1,413,635,355.3
Due to other parties	3,364,908.32	3,764,051.51
Other receivables	6,241,738,372.13	4,714,665,307.07
Non-current liabilities:		
Long-term debt		
Accounts payable	1,672,602,948.04	1,303,756,606.6
Accounts receivable	496,111,943.19	62,232,161.16
Prepaid expenses		
Income tax receivable		
Other receivables	104,240,297.81	104,000,677.4
Due from related parties	339,805.72	2,766.0
Due to related parties	69,187,918.91	13,020,000.00
Due to subsidiaries	9,766,766.17	7,706,665.53
Due to joint ventures	19,742,990.60	16,672,645.6
Due to associates	383,481,900.37	275,353,306.24
Due to other parties		
Other receivables	2,755,474,570.81	2,733,010,114.14
Other receivables	8,997,212,942.94	7,545,512.21

Items	September 30, 2022	August 31, 2022
Owners' equity:		
Common stock	1,467,296,204.00	1,467,296,204.00
Preferred stock		
Retained earnings		
Accumulated other comprehensive income		
Other equity	5,916,624,759.22	5,433,653,365.2
Total equity	192,462,995.09	1,335,615,515.51
Accounts payable		
Accounts receivable	536,799,924.51	536,799,924.51
Inventory		
Prepaid expenses		
Other assets	4,247,863,603.11	3,646,611,117.5
Accounts payable	12,361,047,485.93	11,411,354,455.
Accounts receivable	110,838,792.42	111,605,516.6
Inventory	12,471,886,278.35	11,523,315,415.57
Prepaid expenses	21,469,099,221.29	1,101,175,266.7


 Controller


 Treasurer


 Secretary

2. Consolidated Income Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

Items	Amount for current period	Amount for the corresponding period of the previous year
一、营业收入	5,395,177,444.06	4,631,224,401.56
主营业务收入	5,395,177,444.06	4,631,224,401.56
其他业务收入		
营业外收入		
二、营业成本		
主营业务成本	4,468,505,243.35	4,100,533,757.75
其他业务成本	3,654,541,872.16	3,174,630,000.71
营业外支出		
资产减值损失		
公允价值变动损益		
投资收益		
汇兑损益		
其他收益	9,205,121.29	1,426,536.60
营业外收入	369,120,331.69	2,406,061.43
营业外支出	322,559,393.67	2,247,003.51
其他综合收益	166,593,528.66	10,317,333.77
其他业务成本	-53,515,004.12	230,114,441.37
其他收益	168,243,833.81	151,662,310.61
营业外收入	40,909,565.34	42,251,320.20
营业外支出	32,719,975.34	22,166,104.73
其他综合收益	-81,921,282.69	26,750,460.46
其他业务成本	-83,386,807.18	1,254,640,067.75
其他收益		
营业外收入		
营业外支出		

Items	Amount for current period	
1. <i>...</i>	56,813,153.88	3,261,531.31
2. <i>...</i>		
3. <i>...</i>	-7,370,994.39	4,270,112.26
4. <i>...</i>		
5. <i>...</i>		
(II) <i>...</i>	326,376,991.11	4,011,116.11
1. <i>...</i>	14,161,222.65	10,602,421.21
2. <i>...</i>		
3. <i>...</i>		
4. <i>...</i>		
5. <i>...</i>		
6. <i>...</i>	312,215,768.46	14,615,546.20
7. <i>...</i>		
<i>...</i>	1,371,728.02	10,611.52
<i>...</i>	1,027,254,477.99	460,033,034.11
(I) <i>...</i>	1,028,077,003.26	464,561,111.21

Items	Amount for current period	
(II) 2019-2020	-822,525.27	4,553,076.32
(I) 2019-2020	0.4445	0.3145
(II) 2019-2020	0.4445	0.3145

0.00, 0.00.

2019-2020

2019-2020

2019-2020

3. Consolidated Cash Flow Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

Items	Amount for current period	Amount for the corresponding period of the previous year
一、经营活动产生的现金流量		
销售商品、提供劳务收到的现金	5,636,346,156.36	4,701,106,656.3
收到的税费返还		
收到其他与经营活动有关的现金		
经营活动现金流入小计		
购买商品、接受劳务支付的现金		
支付给职工以及为职工支付的现金		
支付的各项税费		
支付其他与经营活动有关的现金		
经营活动现金流出小计		
经营活动产生的现金流量净额		
二、投资活动产生的现金流量		
收回投资收到的现金		
取得投资收益收到的现金		
处置固定资产、无形资产和其他长期资产收回的现金净额		
处置子公司及其他营业单位收到的现金净额		
收到其他与投资活动有关的现金		
投资活动现金流入小计		
购建固定资产、无形资产和其他长期资产支付的现金		
投资支付的现金		
取得子公司及其他营业单位支付的现金净额		
支付其他与投资活动有关的现金		
投资活动现金流出小计		
投资活动产生的现金流量净额	375,424,510.04	276,734,710.02
三、筹资活动产生的现金流量		
吸收投资收到的现金	72,009,536.97	35,000,051.21
发行债券收到的现金		
收到其他与筹资活动有关的现金		
筹资活动现金流入小计	6,083,780,203.37	5,014,053,170.06
偿还债务支付的现金	5,322,980,702.09	3,625,400,060.1
分配股利、利润或偿付利息支付的现金		
支付其他与筹资活动有关的现金		
筹资活动现金流出小计		
筹资活动产生的现金流量净额		
四、汇率变动对现金及现金等价物的影响		
五、现金及现金等价物净增加额		
期初现金及现金等价物余额		
期末现金及现金等价物余额		

Items	Amount for current period	
	717,088,081.77	5 5,42 ,54 ,
	211,193,118.23	1 5,176,0 3.71
	551,799,391.12	4 5,235, 27.66
	6,803,061,293.21	4, , 1,330,630.26
	-719,281,089.84	122,722,54 . 0
	2,470,118,418.02	2,427,26 ,37 .42
	93,980,404.15	5 7, 1,353.51
	151,844.45	170,362.74
	2,020,354,688.99	1, Q ,6 0,742, 0
	4,584,605,355.61	4, 25,011, 37.57
	162,563,223.26	144,755,500.41
	2,749,695,820.61	1,504,112,301.61
	1,669,992,531.50	2,23 , 16,112.7
	4,582,251,575.37	3, 7,6 3, 14. 0
	2,353,780.24	1,037,327, 22.77
	4,928,822,097.65	2, , 0,440,715.27
	10,997,692.25	
	4,939,819,789.90	2, , 0,440,715.27
	3,627,473,860.07	2, 3 , 17, 57.11
	209,613,269.79	3 2,0 ,306.73

Items	Amount for current period	
	132,516,051.27	36,15 ,407.06
	3,969,603,181.13	3,35 ,164,670, 0
	970,216,608.77	, 467,723, 55.63
	10,585,080.37	, 27,3 5,4 4.60
	263,874,379.54	664, 31,021.34
	1,479,633,434.04	1,330,245,256.17
	1,743,507,813.58	1,, 5,176,277.51

(2) Audit Report